PRESS RELEASE: Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has

Read More

PRESS RELEASE: OncoHelix and Oxford Cancer Biomarkers Enter into a Partnership to Offer Breakthrough Cancer Genetic Screening Test to Canadians

OXFORD, UK – 20th March 2023 – Oxford Cancer Biomarkers (OCB) and OncoHelix today announce a new partnership to offer

Read More

PRESS RELEASE: Oxford Cancer Biomarkers granted Artificial Intelligence in Health and Care Award

OXFORD, UK – 3rd March 2023 – Oxford Cancer Biomarkers Ltd (OCB) announces today the receipt of an important AI

Read More

PRESS RELEASE: Oxford Cancer Biomarkers announces European expansion of life-saving chemotherapy toxicity test and independent, real-world evidence of patient benefit

ToxNav®, a CE-marked in vitro diagnostics product is now registered in the European database on medical devices (EUDAMED).  Independent study

Read More

PRESS RELEASE: Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board

OXFORD, UK – 6th January 2022 – Joanna Smart, an experienced Director and CEO in the life sciences sector has

Read More

Health Economics model for OncoProg® commissioned

            Oxford Cancer Biomarkers Ltd partners with York Health Economics Consortium to demonstrate OncoProg ®

Read More

PRESS RELEASE: OncoProg receives CE mark

Oxford Cancer Biomarkers achieves CE mark for OncoProg ® digital pathology computational software product   OXFORD, UK – July 19th,

Read More

PRESS RELEASE: Kyoung Mee Lee joins our Board of Directors

Oxford Cancer Biomarkers Ltd is pleased to announce that Kyoung Mee Lee has joined our Board of Directors.   OXFORD,

Read More